Eghlidos Zahra, Abolhassanbeigi Aida, Rahimian Zahra, Khazraei Samaneh, Ostovan Vahid Reza
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Psychiatry, Shiraz University of Medical Sciences, Shiraz, Iran.
Parkinsons Dis. 2023 Jun 9;2023:1972034. doi: 10.1155/2023/1972034. eCollection 2023.
We aimed to assess the validity and reliability of the Persian version of the NonMotor Symptoms Scale (NMSS) in Iranian patients with PD.
This cross-sectional study was conducted in patients with PD. After the cross-cultural adaptation of the NMSS, the acceptability, reliability, precision, and validity of the Persian NMSS were evaluated. For this purpose, in addition to NMSS, we used the following measures: Scales for Outcomes in Parkinson's Disease (SCOPA)-Autonomic (SCOPA-AUT), SCOPA-Sleep, Beck's Depression Inventory (BDI) questionnaire, Parkinson's Disease Questionnaire-8 questions (PDQ-8), SCOPA-Motor, SCOPA-Psychiatric Complications (SCOPA-PC), SCOPA-Cognition (SCOPA-COG), Mini-Mental State Examination (MMSE), Hoehn and Yahr Staging (H and Y), and Unified Parkinson Disease Rating Scale (UPDRS).
186 patients were enrolled mean age 64.46 ± 9.9 years; disease duration 5.59 ± 3.99 years; 118 (63.4%) male; mean NMSS score 52.01 ± 38.54). Neither the floor effect (2.7%) nor the ceiling effect (0.5%) was seen in NMSS total score. Cronbach's alpha of total NMSS was 0.84. The test-retest reliability was 0.93 for the NMSS total and 0.81-0.96 for domains. The standard error of measurement (SEM) was lower than half of the standard deviation for NMSS total and all domains. NMSS total showed a high correlation with UPDRS I ( = 0.84), UPDRS II ( = 0.58), PDQ-8 ( = 0.61), BDI ( = 0.71), SCOPA-sleep ( = 0.60), and SCOPA AUT ( = 0.66). NMSS has an acceptable discriminative validity based on disease duration and severity of disease according to H and Y staging.
The Persian NMSS is a valid and reliable measure for evaluating the burden of nonmotor symptoms in Iranian patients with PD.
我们旨在评估波斯语版非运动症状量表(NMSS)在伊朗帕金森病(PD)患者中的有效性和可靠性。
本横断面研究在PD患者中进行。在对NMSS进行跨文化调适后,评估波斯语版NMSS的可接受性、可靠性、精确性和有效性。为此,除NMSS外,我们还使用了以下量表:帕金森病综合评分量表-自主神经功能(SCOPA-AUT)、SCOPA-睡眠量表、贝克抑郁量表(BDI)问卷、帕金森病问卷-8项问题(PDQ-8)、SCOPA-运动功能量表、SCOPA-精神并发症量表(SCOPA-PC)、SCOPA-认知功能量表(SCOPA-COG)、简易精神状态检查表(MMSE)、霍恩和雅尔分期(H和Y)以及统一帕金森病评定量表(UPDRS)。
共纳入186例患者,平均年龄64.46±9.9岁;病程5.59±3.99年;男性118例(63.4%);NMSS平均得分52.01±38.54)。NMSS总分未出现地板效应(2.7%)和天花板效应(0.5%)。NMSS总分的克朗巴哈系数为0.84。NMSS总分的重测信度为0.93,各领域的重测信度为0.81 - 0.96。测量标准误(SEM)低于NMSS总分及所有领域标准差的一半。NMSS总分与UPDRS I(=0.84)、UPDRS II(=0.58)、PDQ-8(=0.61)、BDI(=0.71)、SCOPA-睡眠量表(=0.60)和SCOPA AUT(=0.66)高度相关。根据H和Y分期,NMSS基于病程和疾病严重程度具有可接受的区分效度。
波斯语版NMSS是评估伊朗PD患者非运动症状负担的有效且可靠的工具。